Complete enrollment in the APOLLO-B Phase 3 study
Delivered after the deadline
AI-assessed · human review in progress Found and assessed by AI from the cited sources. Shown with its evidence; it is not counted in any Kept Score until confirmed.
- Announced
- 11 Feb 2021
- Due
- 31 Mar 2021
- Delivered
- Q2 2021
- Deadline
- Met
- Late
- Not met
- Today
What the company said
“Complete enrollment in the APOLLO-B Phase 3 study of patisiran in patients with ATTR amyloidosis with cardiomyopathy.”
What we found
Evidence strength A What the grades mean
The company stated in early 2021 that enrollment was ongoing, and later confirmed that enrollment for the APOLLO-B study was completed in the second quarter of 2021, missing the early 2021 deadline.
-
A Alnylam Pharmaceuticals, Inc. 10-Q filed 2021-04-29
“Continued enrollment in the APOLLO-B Phase 3 study in ATTR amyloidosis patients with cardiomyopathy and remain on track to complete enrollment in early 2021.” ✓ confirmed on the page
-
A Alnylam Pharmaceuticals, Inc. 10-K filed 2022-02-10
“The study enrolled 360 adult patients with confirmed cardiomyopathy and medical history of symptomatic heart failure due to ATTR amyloidosis, with enrollment completed in the second quarter of 2021.” ✓ confirmed on the page
Checked 25 Oct 2026.
Commitment DNA
The structured record of this commitment. Fields the company did not state are left blank rather than guessed.
- Event type
- Clinical milestone
- Indicative materiality
- Medium rules
- Action
- Complete
- Deliverable
- APOLLO-B Phase 3 study enrollment
- In the company’s control
- High
- Specificity
- High
How this entry was checked
- Commitment recordedThe company's words were matched word for word against the filing.
- First checkAn AI model, Gemini (Google), read the company's later filings and recorded the outcome with a quoted passage.
Not yet confirmed. Shown on the record, but it will not count in any score until it is confirmed. How verification works
Are you Alnylam Pharmaceuticals, Inc.? You can publish an official statement next to this entry, free. Add a statement.
Is something here wrong or out of date? Companies and readers can ask us to check it. Please bring a link to a public source.
Report an error in this entry Reference: KI-C-2021-ALNY-023581 · Corrections policy